Personal Injury Lawsuit
Macugen Lawsuit
- Details
- Parent Category: Lawsuit News Alerts
- Category: Personal Injury Lawyer Lawsuit News / Information
Macugen Lawsuit
Macugen Side Effects
Mecugen® is a pegaptanib sodium injection used to treat
neovascular (wet) macular degeneration related to age. It is a sterile,
watery solution for intravitreous injection supplied in a pre-filled, single
dose syringe containing monobasic sodium phosphate monohydrate, sodium
chloride, hydrochloric acid, dibasic sodium phosphate heptahydrate, and/ or
sodium hydroxide to regulate the pH and water for injection.
The active ingredients in Mecugen include:
· 0.3mg- free acid form of oligonucleotide
· 1.6mg of pegaptanib sodium
Pegaptanib sodium is a covalent conjunctive of an
oligonucleotide consisting
of 28 necleotides in length that destructs in pentylamino linker. Two 20-
kilodalton monomethoxy polyethylene glycol (PEG) units are covalently using
the two amino groups on a lysine residue in the pentylamino linker.
Macugen Lawsuit
Macugen Side Effects
Indicated for the treatment of neovascular (wet) macular degeneration related
to age, Macugen is to be administered by intravitreous injection into the eye
once every six weeks. It is critical that Macugen be inspected visually,
prior to admisistration, for particulate matter and discoloration.
The injection procedure of Macugen should be initiated under controlled
aseptic conditions including the use of sterile gloves, a sterile drape, and
sterile eyelid speculum. The pouches should be carefully opened when ready to
assemble syringe and administer injection. The contents should be removed and
placed on a sterile field. If the plastic clip is missing or not attached to
the syringe upon opening the pouch, it should not be used. If there are
bubbles in the syringe contents, the syringe should be held with the needle
pointing up and gently tapped with finger until the bubbles rise to the top
and then the plunger should be slowly depressed to remove the bubbles and
also to expel the excess Macugen.
Prior to administering this drug, the patients’ medical history should be
evaluated for hypersensitive reactions and if present, the proper amount of
anesthesia and broad-spectrum microbicide should be given prior to
application. Patients should be monitored for endorphthalmitis and
intraocular pressure after the injection is given. Any such symptoms should
be reported immediately.
Macugen is should be stored in the refrigerator at 2 ° to 8°C and is supplied
in a sterile foil pouch. The syringe should not be frozen or shook
vigorously.
Less than 1% of the intraviteous injections result in the following adverse
events:
· endophthalmitis
· retinal detachment
· iatrogenic traumatic cataract
The following adverse events are the most frequently reported in patients
treated with Macugen 0.3mg for up to two years:
· anterior chamber inflammation
· blurred vision
· conjunctival hemorrhage
· eye pain
· corneal edema
· eye discharge
· Cataract
· eye irritation
· hypertension
· increased intraocular pressure (IOP)
· ocular discomfort
· punctate keratitis
· reduced visual acuity
· visual disturbance
· vitreous floaters
· vitreous opacities
The following are some side-effects reported in ocular patients:
· blepharitis
· conjunctive
· photopsia
· vitreous disorder
· allergic conjunctivitis
· conjunctival edema
· corneal abrasion
· corneal deposits
· corneal epithelium disorder
· endophthalmitis
· eye inflammation
· eye swelling
· eyelid irritation
· meibomianitis
· mydriasis
· periorbital hematoma
· retinal edema
· vitreous hemorrhage
The following are some side-effects reported in non-ocular patients:
· bronchitis
· diarrhea
· Dizziness
· Headache
· Nausea
· urinary tract infection
· arthritis
· bone spur
· carotid artery occlusion
· cerebrovascular accident
· chest pain
· contact dermatitis
· contusion
· diabetes mellitus
· dyspepsia
· hearing loss
· pleural effusion
· transient ischemic attack
· urinary retention
· vertigo
· vomiting

